中国药业2024，Vol.33Issue(1)：128,后插1-后插4,5.DOI:10.3969/j.issn.1006-4931.2024.01.029
伏美替尼治疗非小细胞肺癌的研究进展
Research Progress on Furmonertinib in the Treatment of Non-Small Cell Lung Cancer
摘要
Abstract
Objective To provide a reference for the rational application of furmonertinib in the clinical treatment of non-small cell lung cancer(NSCLC).Methods Literature related to furmonertinib in the Web of Science and PubMed databases from January 2021 to March 2023 were searched to summarize the research progress on the pharmacokinetic characteristics,clinical efficacy,and adverse drug reactions(ADRs)of furmonertinib.Results The drug metabolism of furmonertinib is related to the dosage and combination therapy.It has good efficacy and safety in the treatment of NSCLC and metastatic NSCLC with epidermal growth factor receptor(EGFR)ex20ins and T790M mutations.In addition to common ADRs such as liver function damage,diarrhea,rash,etc.,furmonertinib also has some rare ADRs such as thrombosis,coagulation dysfunction,hypertension,electrolyte disorders,urinary tract infections,gastrointestinal perforation,and cardiac function damage.Conclusion In clinical application,attention should be paid to monitoring the drug-drug interaction between furmonertinib and other combination drugs.To avoid severe ADR,some examinations such as liver and kidney function,cardiac ultrasound,coagulation function should be carried out for the patients before receiving furmonertinib treatment.关键词
非小细胞肺癌/伏美替尼/酪氨酸激酶抑制剂/药物代谢/药品不良反应Key words
non-small cell lung cancer/furmonertinib/tyrosine kinase inhibitor/drug metabolism/adverse drug reactions分类
医药卫生引用本文复制引用
夏盼盼,范若南,鹿楠楠,沈爱宗..伏美替尼治疗非小细胞肺癌的研究进展[J].中国药业,2024,33(1):128,后插1-后插4,5.基金项目
国家自然科学基金面上项目[52273308] （）
国家自然科学基金青年项目[82203882]. （）
